Madrigal Pharmaceuticals (FRA:YDO1) Net Change in Cash : €-399.5 Mil (TTM As of Mar. 2025)

View and export this data going back to 2007. Start your Free Trial

What is Madrigal Pharmaceuticals Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Madrigal Pharmaceuticals's Net Change in Cash for the three months ended in Mar. 2025 was €77.4 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2025 was €-399.5 Mil.

Madrigal Pharmaceuticals Net Change in Cash Historical Data

The historical data trend for Madrigal Pharmaceuticals's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Madrigal Pharmaceuticals Net Change in Cash Chart

Madrigal Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Net Change in Cash

Get a 7-Day Free Trial

6.01

-15.70

278.75

-212.41

4.87

Madrigal Pharmaceuticals Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Net Change in Cash	Get a 7-Day Free Trial															480.80	-114.19	-235.98	-126.70	77.36

Madrigal Pharmaceuticals Net Change in Cash Calculation

Madrigal Pharmaceuticals's Net Change in Cash for the fiscal year that ended in Dec. 2024 is calculated as

Net Change in Cash	=	Cash Flow from Operations	+	Cash Flow from Investing	+	Cash Flow from Financing	+	Effect of Exchange Rate Changes
	=	-435.071	+	-262.039	+	701.984	+	0
	=	4.9

Madrigal Pharmaceuticals's Net Change in Cash for the quarter that ended in Mar. 2025

Net Change in Cash = Cash Flow from Operations + Cash Flow from Investing + Cash Flow from Financing + Effect of Exchange Rate Changes

= -82.224 + 151.587 + 7.992 + 0

= 77.4

Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-399.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Madrigal Pharmaceuticals Net Change in Cash Related Terms
Thank you for viewing the detailed overview of Madrigal Pharmaceuticals's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Madrigal Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Madrigal Pharmaceuticals Inc (FRA:YDO1) » Definitions » Net Change in Cash

Comparable Companies

BBIO TGTX BPMC LEGN NUVL IONS JAZZ AXSM HALO ADMA VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX

Traded in Other Exchanges

MDGL:USA 0JXI:UK

Address

200 Barr Harbor Drive, Suite 200, Four Tower Bridge, West Conshohocken, PA, USA, 19428

Website

https://www.madrigalpharma.com

Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.

Madrigal Pharmaceuticals Headlines

No Headlines